BEN 01
Alternative Names: BEN-01Latest Information Update: 03 May 2024
At a glance
- Originator Benuvia Therapeutics
- Class Analgesics
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Postoperative pain
Most Recent Events
- 23 Apr 2024 Phase-II clinical trials in Postoperative pain (Inhalation), before April 2024 (Benuvia Therapeutics pipeline, April 2024)